Proposal by the Board of Directors:
Mandatory Convertible Notes
Creation of Conditional Capital
Approval of Article 4a para. 3 of the Articles of Association
A. Motion of the Board of Directors
The Board of Directors proposes the creation of conditional capital
in a maximum amount of CHF 27,775,000 by means of the
following addition to the Articles of Association.
Article 4a para. 3 (new)
Mandatory Convertible Notes
The share capital will be increased by a maximum of CHF
27,775,000 through the issuance of a maximum of 277,750,000
fully paid registered shares with a par value of CHF 0.10 each
upon voluntary or mandatory conversion of the 9% mandatory
convertible notes due 2010 (MCN) to be issued by the Corporation
or one of its subsidiaries to one or several long-term
financial investors. The conditions of the conversion rights under
the MCN shall be determined by the Board of Directors.
The advance subscription right and the pre-emptive right of
the shareholders shall be excluded in connection with the
issuance of the MCN and upon voluntary or mandatory conversion
of the MCN in favor of the MCN holders. The issue price of
the registered shares to be issued upon voluntary or mandatory
conversion of the MCN will be determined by reference to the
respective market price of the registered shares at the time of (i)
the public announcement of the MCN, (ii) the shareholders
approval of this Article 4a para. 3, and (iii) the conversion of the
MCN. The voluntary or mandatory conversion of the MCN is to
occur within a period of two years after the issuance of the MCN.
The acquisition of shares upon voluntary or mandatory conversion
of the MCN as well as any subsequent transfer of the
shares are subject to the registration requirements set out in
Article 5 of these Articles of Association.
B. Explanations
The Board of Directors intends to issue mandatory convertible
notes (MCN) in the amount of CHF 13 billion to two long-term
financial investors. These investors have agreed to subscribe for
CHF 11 billion and CHF 2 billion, respectively. The notes mature
at the latest in two years (expected 5 March 2010). Through the
lifetime of the MCN, the holders of the notes will receive an
annual coupon of 9% of the nominal value of the notes, but no
dividends on the underlying shares.
Existing shareholders will not be granted advance subscription
rights. This statutory right may be excluded for valid reasons.
The Board of Directors, when proposing that the advance subscription
right of the shareholders is excluded, has to determine
whether the exclusion of advance subscription rights is in the
best interest of the company and whether it is necessary to achieve the desired aim. Considering the recent substantial
write-downs and their impact on the capital position of UBS
AG, and given the current situation of the financial markets, the
Board of Directors concluded that an immediate strengthening
of the capital base of the company was the overriding objective
which needed to be achieved immediately. This objective could
only be realized if investors could commit new capital immediately
and on a firm basis. The Board of Directors therefore concluded
that an issuance of MCNs at the exclusion of advance
subscription rights of existing shareholders was justified under
the circumstances. Other alternatives, most notably a rights
offering, would not have led to the same certainty in funding of
UBS AG and would not, therefore, have had the desired effect
of strengthening the UBS AG capital base immediately.
As explained in some detail in the Shareholder Information
Brochure dated 31 January 2008 under the heading Mandatory
Convertible Notes, the minimum number of UBS shares to be
delivered upon conversion of the MCN is expected to be 176.6
million, and the maximum number is expected to be 252.5 million.
However, if dilutive events (such as capital increases at a discount
and dividends in cash or in specie above CHF 2.20 in 2008
or 2009) occur prior to conversion, the conversion price(s) will be
adjusted, which will increase the maximum number of shares.
Therefore, UBS proposes to its shareholders to approve the creation
of conditional capital in the amount of 277.75 million
shares; the higher number of shares is designed to provide headroom
should dilutive events occur prior to conversion.
For further information, in particular as to the exclusion of the
advance subscription rights, the terms and conditions of the MCN
and the number of shares to be issued upon conversion, please
refer to Letter to Shareholders dated 10 January 2008 and to the Shareholder Information Brochure dated 31 January 2008 under the heading "Mandatory Convertible Notes".
Alternative Proposal by Profond:
Ordinary Capital Increase
Rights Offering
C. Motion of Profond
Profond proposes that as an alternative to the creation of conditional
capital for the purpose of issuing the MCN, UBS AG shall effect
an ordinary capital increase with subscription rights allotted to
existing shareholders (rights offering). The rights offering should
be structured in a manner that also results in proceeds in the
amount of CHF 13 billion. The proposal of Profond would lead to
an ordinary capital increase with the following parameters:
1. Increase of the share capital from the current CHF
207,225,328.60 by a maximum amount of CHF 52,000,000
to a maximum of CHF 259,225,328.60 through the issuance
of a maximum of 520,000,000 fully paid registered shares
with a par value of CHF 0.10 each at an issue price of CHF 0.10.
The final number of shares to be issued will be determined
by the Board of Directors shortly before the launch of the
rights offering and will be set at a number that results in net
proceeds to UBS AG of approx. CHF 13 billion.
2. The Board of Directors is authorized to determine the subscription
price. The new shares to be issued shall be entitled
to dividends from the financial year 2008.
3. The contributions for the new shares to be issued shall be
effected in cash.
4. The new shares shall have no preferential rights.
5. The new shares to be issued are subject to the registration requirements
set out in Article 5 of the Articles of Association.
6. The subscription rights of the current shareholders shall be
granted directly or indirectly. Shares in respect of unexercised
subscription rights are to be sold at market conditions.
7. The Board of Directors shall effect the capital increase and
file for its registration with the Commercial Register within
three months from the shareholders meeting.
Profond has submitted its motion as an alternative to the
proposal of the Board of Directors referred to in agenda item
3.A above. If the original proposal of the Board of Directors to
create conditional capital underlying the MCN is approved by
the shareholders, the alternative proposal submitted by Profond
will not be voted upon since the two proposals exclude each
other, i.e., it is not possible to have both proposals approved.
The Board of Directors proposes to reject the proposal of Profond
for the reasons set out below.
Prior to announcing the capital improvement measures on 10 December
2007, the Board of Directors considered but ultimately
did not pursue the option of a rights offering. A rights offering
would not have created the certainty of an immediate commitment
of fresh capital. In addition, a rights offering features a
number of disadvantages compared to the issuance of the MCN:
A rights offering is likely to be unsuccessful if the market
price of the offered shares falls below the subscription price.
For this reason, rights offerings are generally conducted at a
discount to current market prices.
A rights offering will need to be fully underwritten by a syndicate
of banks or otherwise guaranteed by a third party. If
the rights offering is not underwritten, there is no certainty
whether any new capital can be raised at all, and how much
can be raised.
Given the discount required in connection with a rights offering
in the current market environment, UBS may have to
offer up to 520 million shares to achieve net proceeds of
CHF 13 billion. This number is substantially higher than the
number of shares required for the issuance of the proposed
MCN (up to 277.75 million shares) yielding the same amount
of proceeds. For shareholders who do not take up their
rights, this means a substantial dilution.
A rights offering would have to be structured as a public offering
in several jurisdictions to allow as many shareholders as possible
to participate in the offering. In this connection, UBS AG
needs to prepare a prospectus and have the same approved by
the competent regulatory authorities in Switzerland and the European
Union (in addition to filings in the United States of
America). The time required to prepare and seek approval for a
rights offering will significantly delay the issuance of new shares
and the closing of the capital improvement measures planned
by UBS. It would hardly be possible to close the rights offering
within the statutory timeframe of three months.
The statutory timeframe of three months also does not provide
enough flexibility in case of unforeseen events or market
disruptions.
The announcement of a rights offering of this size would
cause downward pressure on our share price, and thus
would increase the uncertainty both as to the success of and
the proceeds expected from a rights offering.
The Board of Directors, therefore, determined that the issuance
of an MCN to two long-term financial investors was in the best
interests of UBS and its shareholders, and preferable to any
other option. Further explanations can be found in the Shareholder Information Brochure dated 31 January 2008 under the heading "Mandatory Convertible Notes".